Australia's CSL Eyes Outselling Baxter In U.S. Immunoglobin Market
This article was originally published in PharmAsia News
Executive Summary
CSL of Australia stands to become the leading U.S. seller of an immunoglobin substitute, thanks to its popular Hizentra